

CURRICULUM VITAE**GARY STUART HOFFMAN, M.D., M.S., F.A.C.P., F.A.C.R.**

Chairman, Department of Rheumatic and Immunologic Diseases / A50

Director, Center for Vasculitis Care and Research

The Harold C. Schott Chair

The Cleveland Clinic Foundation

9500 Euclid Avenue

Cleveland, OH 44195

5570

5533

5539

PERSONAL**EDUCATION**

1964 B.A. Biology, Harpur College, SUNY in Binghamton, New York

1967 M.S. Zoology, Howard University, Washington, D.C.

1971 M.D. Medical College of Virginia, Richmond, Virginia

RESEARCH / PROFESSIONAL EXPERIENCE

1971-1972 Internship in Medicine, Riverside Hospital, Newport News, Virginia

1972-1973 Residency in Medicine, Mary Hitchcock Memorial Hospital, Dartmouth Medical School, Hanover, New Hampshire

1973-1974 Fellowship in Rheumatology, Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire

1974-1976 Chief, Rheumatology, Letterman Army Medical Center, U.S. Army, Presidio of San Francisco, California. Instructor in Medicine and member of Rheumatic Disease Section, University of California in San Francisco, California

1976-1977 Chief of Rheumatology, Assistant Professor of Medicine, White River Junction Veterans Administration Hospital, White River Junction, Vermont. Dartmouth Medical School, Hanover, New Hampshire

1977-1986 Chief of Rheumatology, Mary Imogene Bassett Hospital, Cooperstown, New York. Associate Professor of Clinical Medicine, Columbia University, College of Physicians and Surgeons.

1986-1987 Director of Internal Medicine. Associate Professor of Medicine. State University of New York, Upstate Medical Center. Clinical Campus in Binghamton.

1987-1990	Expert, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
1990-1992	Senior Investigator, Tenure, Laboratory of Immuno-regulation, NIAID, NIH, Bethesda, MD
1991-1992	Head, Vasculitis and Related Diseases Section, Laboratory of Immunoregulation, NIAID, NIH, Bethesda, MD
1992 - present	Chairman, Department of Rheumatic and Immunologic Disease, Cleveland Clinic Foundation, Cleveland, Ohio
1999 - present	Director Center for Vasculitis Care and Research, CCF

ACADEMIC APPOINTMENTS

1994 - Professor of Medicine, Ohio State University
 2000 - Harold C. Schott Chair in Rheumatic and Immunologic Diseases

BOARD CERTIFICATION

National Boards - 1972
 American Board of Internal Medicine (—) - 1976
 Board Certified in Rheumatology (—) 1978

PROFESSIONAL ASSOCIATION MEMBERSHIPS

Fellow American College of Physicians
 Fellow American Rheumatism Association
 Otsego County Medical Society
 New York State Medical Society
 Board of Directors, Central New York State Arthritis Foundation
 Association for Hospital Medical Education
 International Network for the Study of the Systemic Vasculitides (INSSYS)
 Founder and Chairman (1991-present)
 Wegener's Granulomatosis International Support Group
 Consultant Staff 1996-present
 Wegener's Foundation
 Board of Directors 1994-1999
 Churg Strauss Vasculitis International Support Group
 Board of Directors 1998-present
 Takayasu's Arteritis Foundation Advisory Board 1999-present

STATE LICENSES

New York : —
 New Hampshire : —
 Vermont : —
 California : —
 Ohio : —

SPECIAL PROGRAMS: Cleveland Clinic Foundation Office of Practice Management and Case-Weatherhead School of Business, Executive Management Program in Health Care Administration - 1993.

HONORS

Golden Apple Award for teaching excellence - 1985
Award for Teaching Excellence - 1995, 1998
National Institutes of Health, NIAID Director's Award, 1990, 1992
For overall performance in contributing to Institute goals - 1990
NIH Director's Award - 1992
Chairman and Founder – 1991-present
International Network for the Study of Systemic Vasculitis
Honorary Member of the Chilean Society of Rheumatology - 1995
“Best Doctors in America: General Rheumatology”, 1996, 1997, 1998, 1999
Castle Connolly’s “America’s Top Doctors” 2001
The Twenty-Second Annual William K. Ishmael Award and
Lectureship in Rheumatology (1996), University of Oklahoma
Mexican Society of Rheumatology, Annual Visiting Professor, 1998.
National Institutes of Health, National Institute of Allergy and
Infectious Diseases Advisory Panel for Vasculitis Research -1998
National Institutes of Health, National Institute of Arthritis and
Musculoskeletal and Skin Diseases, long range planning panel – 1999

Board of Directors, American College of Rheumatology 2000-

Keynote and Co-Chair, Vasculitis. Japanese Society of Rheumatology, 2001.

REVIEWER FOR JOURNALS

Allergy and Immunology
American Review of Respiratory Diseases
Annals of Internal Medicine
Annals of Rheumatic Diseases
Arthritis and Rheumatism
Chest
Cleveland Clinic Journal of Medicine
Clinical and Experimental Rheumatology
Clinical and Experimental Immunology
International Archives of Allergy and Immunology
Journal of Clinical Immunology
Journal of Molecular Medicine
Journal of Rheumatology

Laboratory Investigation
Lancet
Medicine
Neurology
New England Journal of Medicine
Scandinavian Journal of Medicine
Scandinavian Journal of Rheumatology
Southern Medical Journal

EDITORIAL RESPONSIBILITIES

Committee for Publication of *Arthritis Rheumatism* 1993-95
Chairman, Committee for Publication of *Arthritis Rheumatism* 1997-8
Chairman, Publication Committee of the American College of
Rheumatology 1998-2000
Deputy Editor, *Cleveland Clinic Journal of Medicine*
Editor, *Current Opinion in Rheumatology*: Vasculitic Syndromes 1994-1999
Editorial Board, *Clinical and Experimental Rheumatology*, 1998-
Editorial Board, *Journal of Rheumatology*, 1998-
Advisory Editorial Board, *Arthritis and Rheumatism*, 1996-
UpToDate: Editor, Immunosuppressive agents. 1999-
Arthritis Care and Research Task Force 1998-99
Editorial Board, *RheumatologyWeb.com* 2000-
Editorial Board, *Current Opinion in Rheumatology* 2001-

Books edited:

Inflammatory Diseases. of Blood Vessels. Marcel Dekker, Inc.
Hoffman GS and Weyand C. 2001.
Alarcon G and Hoffman GS. Balliere's Clinical Rheumatology.
Vasculitis. 2001.

RECENT SPECIAL CITATIONS AND LECTURESHIPS

Keynote Speaker:
Ten Topics in Rheumatology, "The Rise and Rise of Vasculitis",
St. Thomas' Postgraduate Center, London, July 1996
The Twenty-Second Annual William K. Ishmael Lectureship
in Rheumatology (1996), University of Oklahoma
The Annual Evan's Lecture (1996), "Wegener's
Granulomatosis: The Path Traveled Since 1931",
University of Missouri, Kansas City
International Wegener's Granulomatosis Support Group,
Keynote Speaker, Kansas City, Missouri, 1996
XIXth ILAR Congress of Rheumatology, Singapore, 1997
"Management of Takayasu's Arteritis"
"Pathogenesis of ANCA-Associated Vasculitides"

"Dilemmas in Vasculitis: Diagnosis and Treatment"
 "Recent Advances in Vasculitis"
 Mexican Society of Rheumatology, Annual Meeting 1998
 Keynote Speaker: "Pathogenesis of Systemic Vasculitis"
 International Wegener's Granulomatosis Support Group,
 Keynote Speaker, Kansas City, Missouri, 1999
 The Tisdale Memorial Lecture. University of Vermont. June 9, 2000.
 Achievement Award ACR/Research and Education Preceptorship
 Program 2000.
 JFL Woodbury Lecture, Dalhousie University, Pathogenesis of Systemic
 Vasculitis. 2001
 Sommer Memorial Lecture Series, 1. Pathogenesis of Systemic Vasculitis; 2.
 Wegener's granulomatosis; 3. Distinguishing the systemic vasculitides from
 each other and other diseases. Portland. 2001
 Keynote and Co-Chair, Vasculitis. Japanese Society of Rheumatology;
 Pathogenesis of Systemic Vasculitis; Wegener's granulomatosis. Giant cell
 arteritis. 2001.
 New England Society of Rheumatology. "Pathogenesis of Systemic Vasculitis"
 2001.

ADMINISTRATIVE SERVICES

House Officer Selection Committee	1976-87
Quality Assurance Committee	1978-87
Rheumatology/Physical Medicine Committee	1978-86
Research Advisory Committee (Chairman)	1980-86
Central NY Arthritis Foundation, Board of Directors	1980-86
Curriculum Committee, Internal Medicine (Chairman)	1986-87
Curriculum Committee, Rheumatology (Chairman)	1986-87
NIH/NIAID Medical Review Board (IRB)	1990-92
Chief, Rheumatology	1974-86
Director, Internal Medicine	1986-87
Head, Vasculitis and Related Diseases	1991-92
International Network for the Study of the Systemic Vasculitides, Chairman	1991-present
Chairman, Rheumatic and Immunologic Diseases	1992-present
Board of Directors, Wegener's Foundation	1994-1999
Consultant Staff, Wegener's Granulomatosis International Support Group	1996-present
Professional Advisory Board, CCF Health Care Ventures, Rehabilitation Facility	1997-1999
American College of Rheumatology, Committee on Education	1997-1998
American College of Rheumatology, Publication Committee for <i>Arthritis and Rheumatism</i> (Chairman)	1997-98
American College of Rheumatology,	

Chair Publication Committee American College of Rheumatology,	1998-present
Chair Abstract Subcommittee, Vasculitis, Sjogren's, Phospholipid antibody syndrome	1998
American College of Rheumatology,	
Chair Abstract Subcommittee, Vasculitis	1999
Consultant for Johns Hopkins Multipurpose Clinical Research Center	1999

PATENTS

Cid MC, Grant DS, Hoffman GS, Kleinman HK: For "Method of stimulating angiogenesis by using haptoglobin". U.S. Patent Application Serial No. 07/939, 142, accepted 1993.

ACTIVE RESEARCH PROJECTS

- 1) A Multicenter, Randomized, Double-Blind Study of Glucocorticoids and Methotrexate versus Glucocorticoids and Placebo for Treatment of Giant Cell (Temporal) Arteritis, Principal Investigator, FDA and Storer Foundation.
- 2) The Value of Vascular Activation Markers in Assessing Disease Activity in Patients with Systemic Vasculitis. Principal Investigator: Dr. G.S. Hoffman, Co-Investigators: Dr. Alaa Ahmed (Specialty Laboratories, Santa Clara, CA), International Network for the Study of Systemic Vasculitides.
- 3) The Utility of MRI in Monitoring Large Vessel Vasculitis. Principal Investigators: Drs. G.S. Hoffman and S. Flamm.
- 4) The specificity of ANCA in patients with multi-organ failure and inflammatory lung diseases. PIs: Drs. Dimitrios Vassilopoulos, Gary Hoffman and co-investigators: Drs. John Niles (Harvard/MGH), Peter Merkel (Boston U.), Alex Arrooga and Eugene Sullivan (CCF). CCF Vasculitis Research Fund.
- 5) The utility of Enbrel in the treatment of Wegener's granulomatosis. Phase II/III study. NIH, NIAMS and FDA. Co-PIs: Dr. John Stone (Johns Hopkins), Dr. Gary Hoffman.
- 6) Phase II/III trial of collagen tolerance-induction in scleroderma. Dr. Gary Hoffman, CCF site PI. Project PI for multicenter study: Dr. Arnold Postlethwaite (U. Tenn). NIH, NIAMS.
- 7) Utilization of molecular techniques to identify a role for infectious agents in the pathogenesis of systemic vasculitis. Co-PIs Drs. Gary Hoffman and Herbert Virgin (Washington U. St. Louis). NIH.

OTHER GRANT SUPPORT

Educational Support Grant from the American College of Rheumatology: High Impact Rheumatology. Program Directors: GS Hoffman (Cleveland Clinic Foundation) and Roland Moskowitz (Case Western Research University Medical Center).

PRIOR FUNDED RESEARCH

- 1) Influence of chloroethyl-otriazeno-imidazole-carboxamide on L1210 murine leukemia. Principal Investigator: GS Hoffman. National Cancer Institute
- 2) Adaptation of colorimetric method to quantify chloroethyl-triazeno-imidazole-carboxamide in blood. Principal Investigator: GS Hoffman. National Cancer Institute 1967-68
- 3) Sequential chemotherapy with cyclophosphamide and cytosine arabinoside in mice with advanced leukemia L1210. Principal Investigator: GS Hoffman. National Cancer Institute 1967-68
- 4) Arachnoiditis in dogs: A possible model for human disease. Principal Investigator: GS Hoffman. Funding: Research Institute of the Mary Imogene Bassett Hospital 1981
- 5) Study of oxalate arthropathy in end-stage renal failure in humans. Principal Investigator: GS Hoffman. Funding: Mary Imogene Bassett Hospital Research Institute 1984-85
- 6) Study of calcium oxalate tissue injury in the rat remnant kidney model for chronic renal failure. Principal Investigator: GS Hoffman. Funding: Mary Imogene Bassett Hospital Research Institute 1984-85
- 7) Study of the utility of trimethaprim sulfamethoxizole in the treatment of limited forms of Wegener's granulomatosis. Principal Investigator: GS Hoffman. NIH/NIAID 1989-91
- 8) Interpretation of head and neck biopsies in Wegener's granulomatosis. Pathologic study of 126 biopsies in 70 patients. Principal Investigators: KO Devaney, WD Travis; Co-Investigators: GS Hoffman, RY Leavitt, AS Fauci. NIH/NIAID 1988-90.
- 9) Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Principal Investigator: GS Hoffman. NIH/NIAID 1988-89
- 10) Endothelins: Peptides with potent vasoactive properties are produced by human macrophages. Principal Investigator: H. Ehrenreich. Co-Investigators: RW Anderson, CH Fox, P Rieckmann, GS Hoffman, et al. NIH/NIAID 1989-90
- 11) Antineutrophil cytoplasmic antibody production in the respiratory tract of patients with Wegener's granulomatosis. Principal Investigator: GS Hoffman. NIH/NIAID 1989-90
- 12) Surgical pathology of the lung in Wegener's granulomatosis. Principal Investigator: WD Travis, Co-Investigators: GS Hoffman, RY Leavitt, HI Pass, AS Fauci, NIH/NIAID 1989-90
- 13) Study of intractable vasculitis, resorptive osteolysis and immunity to type I collagen in type IV Ehlers Danlos syndrome. Principal Investigator: GS Hoffman. NIH/NIAID 1989-90
- 14) Prospective analysis of Wegener's granulomatosis at the National Institutes of Health. Principal Investigator: GS Hoffman. NIH/NIAID 1988-91
- 15) Establishment of a registry and database for vasculitis at the National Institutes of Health. Principal Investigator: GS Hoffman. NIH/NIAID 1988-92
- 16) Treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Principal Investigator: GS Hoffman. NIH/NIAID 1988-92
- 17) Development of new techniques to treat subglottic stenosis in Wegener's granulomatosis. Principal Investigator: RS Lebovics. Co-Investigators: GS Hoffman, RY Leavitt, GS Kerr, et al. NIH/NIAID 1988-92
- 18) Study of the prognostic value of antineutrophil cytoplasmic antibodies in patients with Wegener's granulomatosis. Principal Investigator: GS Hoffman. NIH/NIAID 1988-92

- 19) Prospective study of Wegener's granulomatosis in children and adolescents. Principal Investigator: GS Hoffman. NIH/NIAID 1988-92
- 20) Study of angiogenic factors from sera of patients with systemic vasculitis. Principal Investigator: MC Cid, Co-Investigators: DS Grant, HK Kleinman, GS Hoffman, et al. NIH/NIAID 1990-92
- 21) Long-term study of Takayasu's arteritis at National Institutes of Health. Principal Investigator: GS Hoffman. NIH/NIAID 1988-92
- 22) Treatment of glucocorticoid-resistant or relapsing Takayasu's arteritis with methotrexate. Principal Investigator: GS Hoffman. NIH/NIAID 1988-93
- 23) The effect of estrodial on leukocyte binding to activate endothelial cells. Principal Investigator: MC Cid, Co-Investigators: HK Kleinman, DS Grant, HW Schnaper, AS Fauci, GS Hoffman. NIH/NIAID 1990-92
- 24) The utility of indium-111 mixed leukocyte scans to detect active disease in Takayasu's arteritis. Principal Investigator: GS Hoffman. NIH/NIAID 1990-92
- 25) The epidemiology of Wegener's granulomatosis. Principal Investigator: MF Cottch, Co-Investigators: GS Hoffman, DE Yerg, GI Caufman, P Targonski, RA Kaslow. NIH/NIAID 1990-92
- 26) Cyclophosphamide-induced cystitis in bladder cancer in patients with Wegener's granulomatosis. Principal Investigator: C Talar-Williams, Co-Investigators: GS Hoffman, MC Sneller, AS Fauci, et al. NIH/NIAID 1988-92
- 27) Clinical features and management of subglottic stenosis in patients with Wegener's granulomatosis. Principal Investigator: GS Hoffman. NIH/NIAID 1988-92
- 28) The frequency of mediastinal masses and hilar adenopathy in patients with Wegener's granulomatosis. Principal Investigator: GS Hoffman. Cleveland Clinic Foundation, NIH/NIAID 1994-96
- 29) Analysis of Fcγ receptors in Wegener's granulomatosis. Principal Investigator: RP Kimberly, Co-Investigators: JC Edberg, E Weinstein, GS Hoffman et al. NIH Funding through grant to Dr. Kimberly.
- 30) Patient-reported effects of disease on health, function and income in Wegener's granulomatosis. Principal Investigator: GS Hoffman. Cleveland Clinic Foundation. Also funded by The Edward Lozick and Marvin and Olga Esch Foundations for Vasculitis Research 1993-95.
- 31) Role of environmental exposures in precipitating Wegener's granulomatosis. Principal Investigator: GS Hoffman. Cleveland Clinic Foundation, NIH/NIAID 1988-95
- 32) Clinical application of "edema-weighted" magnetic resonance imaging in Takayasu's arteritis. Principal Investigators: GS Hoffman, SD Flamm. Cleveland Clinic Foundation 1995-98
- 33) Surrogate markers of disease activity in patients with systemic vasculitides. Principal Investigator: GS Hoffman. Cleveland Clinic Foundation, Specialty Laboratories 1994-98

COMMITTEES (excluding publication)

Chairman and Founder, 1992 to Present

International Network for the Study of Systemic Vasculitides

Abstract Selection Committee for the American College of Rheumatology

1993, 1994, 1995
American College of Rheumatology,
Chair Abstract Subcommittee, Vasculitis, Sjogren's syndrome,
Phospholipid antibody syndrome, 1998.
Chair Abstract Subcommittee, Vasculitis 1999.
Chairman, American College of Rheumatology Vasculitis Study Group,
1993, 1994, 1995
5 Year Review Committee for the Department of Pulmonary
and Critical Care Medicine
Search Committee for Chairman, Immunology, CCF Research Institute 1997
Search Committee for Chairman, Orthopedics, CCF 1999
Search Committee for Chairman, Anatomic Pathology, CCF 2001
Search Committee for Chairman, Biostatistics, CCF 2001
Nominating Committee, Association of Rheumatology Health Care Professionals 2001

**APPEARS THIS WAY
ON ORIGINAL**

PUBLICATIONS

1. Hoffman GS, Kline I, Gang M, Tyrer DD, Venditti JM, Goldin A: Influence of treatment schedules and route of administration on the chemotherapy of murine leukemia L1210 with 5 (or 4)-(3,3-Bis)(2-chloroethyl)-1-triazeno-imidazole-4 (or 5)-carboxamide (NSC-82196). *Cancer Chemotherapy Rep* 52:715-24, 1968.
2. Field RB, Hoffman GS, Waravedekar VS, Kline I: Adaptation of a colorimetric determination of 5-(3,3-dimethyl-triazeno)-imidazole-4 carboxamide (NSC-45388) and 5-(3, 3-bis (2-chlorethyl)-1-triazeno) imidazole-4-carboxamide (NSC-82196) to blood. *Cancer Chemotherapy Rep* 53:199-202, 1969.
3. Hoffman GS, Kline I, Gang M, Tyrer DD, Goldin A, Venditti JM: Sequential chemotherapy with cyclophosphamide (NSC-26271) and cytosine arabinoside (NSC-63878) in mice with advanced leukemia L1210. *Cancer Chemotherapy Rep* 53:265-71, 1969.
4. Harris ED, Hoffman GS, McGuire JL, Strosberg JM: Colchicine: effects upon urinary hydroxyproline excretion in patients with scleroderma. *Metabolism* 24:529-35, 1975.
5. Hoffman GS: Treatment of lupus erythematosus. *Ann Intern Med* 84:337-8, 1976.
6. Hoffman GS: Treatment of Sweet's Syndrome (acute febrile neutrophilic dermatosis) with indomethacin. *J Rheumatol* 4:201-6, 1977.
7. Hoffman GS: Polyarthritis: the differential diagnosis of rheumatoid arthritis. *Semin Arthritis Rheum* 8:115-41, 1978.
8. Hoffman GS, Myers RL, Stark F, Thoen CD: Septic arthritis associated with *Mycobacterium avium*: case report and literature review. *J Rheumatol* 5:199-209, 1978.
9. Peck B, Hoffman GS, Franck WA: Thrombophlebitis in systemic lupus erythematosus. *JAMA* 240:1728-30, 1978.
10. Hoffman GS, Franck WA: Infectious mononucleosis, autoimmunity and vasculitis. *JAMA* 241:2735-6, 1979.
11. Franck WA, Hoffman GS, Davis JS, et. al.: Osteomalacia and weakness complicating jejunoileal bypass. *J Rheumatol* 5:51-6, 1979.

12. Hoffman GS, Harris ED: Differential diagnosis of rheumatoid arthritis. In: The Science and Practice of Clinical Medicine. Vol. 4. Rheumatology and Immunology. Eds: A. Grune and Stratton, Inc., 1979.
13. Dimauro S, Miranda AF, Hays AP, Franck WA, Hoffman GS, Shoenfeldt Singh N: Myoadenylate deaminase deficiency. Muscle biopsy and muscle culture in a patient with gout. *J Neurolog Sci* 47:191, 1980.
14. Killian PJ, Hoffman GS: Coexistence of systemic lupus erythematosus and myasthenia gravis. *Southern Med J* 73:244-6, 1980.
15. Hoffman GS: Raynauds disease and phenomenon. *Amer Fam Phys* 21:91-7, 1980.
16. Hoffman GS: Rheumatoid nodulosis. *Consultant* p. 122, September, 1980.
17. Zulman JI, Talal N, Hoffman GS, Epstein WV: Problems associated with the management of pregnancies in patients with systemic lupus erythematosus. *J Rheumatol* 7:37-49, 1980.
18. Hoffman GS: Tendinitis and bursitis. *Amer Fam Phys* 23:103-10, 1981.
19. Hoffman GS: Intra- and periarticular steroid therapy. Guest Editorial. *Amer Fam Phys* 23:106-8, 1981.
20. Hoffman GS: Mycobacterial and fungal infections of bones and joints. Chapter 97. In: Textbook of Rheumatology, 1st Ed. Eds: W.N. Kelley, E.D. Harris, S. Ruddy and C.B. Sledge. W.B. Saunders Co. 1981.
21. Hoffman GS, Schumacher HR, Paul H, Cherian V, Reed RG, Ramsay AG, Franck WA: Calcium oxalate microcrystalline arthritis in end stage renal disease. *Ann Intern Med* 97:36-42, 1982.
22. Huyck CJ, Hoffman GS: Joint ankylosis in progressive systemic sclerosis. *Arthritis Rheum* 25:1497-1500, 1982.
23. Hoffman GS: Spinal arachnoiditis: what is the clinical spectrum? Part I. *Spine* 8:538-40, 1983.
24. Hoffman GS, Ellsworth CA, Wells EE, Franck WA, Mackie RW: Spinal arachnoiditis: what is the clinical spectrum? Part II. Arachnoiditis in dogs: A possible model for human disease. *Spine* 8:541-51, 1983.
25. Hoffman GS, Franck WA, Raddatz DA, Stallones L: Presentation, treatment and prognosis of idiopathic inflammatory muscle disease in a rural hospital. *Am J Med* 75:433-8, 1983.

26. Wilkens KW, Hoffman GS: Massive ascites in systemic lupus erythematosus. *J Rheumatol* 12:571-4, 1985.
27. Hoffman GS: Mycobacterial and fungal infections of bones and joints. Chapter 97. In: Textbook of Rheumatology, 2nd Ed. Eds: W.N. Kelley, E.D. Harris, S. Ruddy and C.B. Sledge. W.B. Saunders Co. 1985.
28. Hoffman GS, Reed RG, Guiney WB, Wells EE, Oldroyd NO: Limitations of the rat remnant kidney model of chronic renal failure: absence of calcium oxalate tissue injury. *Nephron* 4:330-4, 1986.
29. MoDrak MA, Hoffman GS: The painful elbow: a guide to differential diagnosis. *Hospital Med* 47-73, March, 1987.
30. Foltzer MA, Hoffman GS: Gonococcal arthritis. Part I. *Intern Med Specialist* 8:177-84, 1987.
31. Raddatz DA, Hoffman GS, Franck WA: Septic bursitis: presentation, treatment and prognosis. *J Rheumatol* 14:1160-3, 1987.
32. Sentochnik DE, Hoffman GS: Hypoparathyroidism due to progressive systemic sclerosis. *J Rheumatol* 15::711-3, 1988.
33. Leavitt RY, Hoffman GS, Fauci AS: The role of trimethoprim-sulfamethoxazole in the treatment of Wegener's granulomatosis. *Arthritis Rheum* 31:1073-4, 1988.
34. Hoffman GS, Sentochnik DE: Mycobacterial and fungal infections. Chapter 89. In: Textbook of Rheumatology, 3rd Ed. Eds: W.N. Kelley, E.D. Harris, S. Ruddy and C.B. Sledge. W.B. Saunders Co. 1989.
35. Fauci AS, Hoffman GS: Granulomatous hepatitis. Chapter 97. In: Principles and Practice of Infectious Diseases, 3rd Edition. Eds: G. Mandel, R.G. Douglas, J. Bennett. J. Wiley and Sons, Inc. 1989.
36. Kerr GS, Hoffman GS: Fluoride therapy for otosclerosis. *Ear Nose Throat J* 68:426-9, 1989.
37. Hoffman GS, Groff GD, Olson JE: Pelvic and hip girdle masses as a cause of "hip" pain: the importance of examining the buttock region. *J Musculoskel Med* p 111-22, June 1989.
38. Hoffman GS, Kerr GS: Gastrointestinal emergencies. Vasculitis and the gut. In: Current Topics in Gastroenterology and Hepatology. Eds: G.N.J. Tytgat and M. van Blankenstein, Thieme Verlag, p 36-54, 1990.

39. Devaney KO, Travis WD, Hoffman GS, et al.: Interpretation of head and neck biopsies in Wegener's granulomatosis: a pathologic study of 126 biopsies in 70 patients. *Am J Surg Path* 14:555-64, 1990.
40. Hoffman GS, Leavitt RY, Fleisher TA, Minor JR, Fauci AS: Treatment of Wegener's granulomatosis with intermittent high dose intravenous cyclophosphamide. *Amer J Med* 89:403-10, 1990.
41. Ehrenreich H, Anderson RW, Fox CH, Rieckmann P, Hoffman GS, Travis WD, Coligan JE, Kehrl JH, Fauci AS: Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. *J Exp Med* 172:1741-8, 1990.
42. Giordano JM, Leavitt RY, Hoffman GS, Fauci AS: Experience with surgical treatment for Takayasu's disease. *Surgery* 109:252-8, 1991.
43. Hoffman GS: Arthritis due to deposition of calcium crystals. Chapter 282, p 1479-82. In: Harrison's Principles of Internal Medicine, 12th Ed. Eds: J.D. Wilson et al. McGraw-Hill Book Company 1991.
44. Hoffman GS, Fauci AS: Respiratory disease in patients treated with glucocorticosteroids (GCS). Chapter 43, p. 682-9. In: Respiratory Disease in the Immunosuppressed Host, 1st Ed. Eds: J.H. Shelhamer, P.A. Pizzo, J.E. Parrillo and H. Masur. J.B. Lippincott Co.1991.
45. Baltaro RJ, Hoffman GS, Sechler JMG, Suffredini AF, et. al.: Antineutrophil cytoplasmic antibodies are produced in the respiratory tract of patients with Wegener's granulomatosis. *Amer Rev Resp Dis* 143:275-8, 1991.
46. Hoffman GS, Sechler JMG, Gallin JI, Shelhamer JH, et. al.: Bronchoalveolar lavage analysis in Wegener's granulomatosis: a method to study disease pathogenesis. *Amer Rev Resp Dis* 143:401-7, 1991.
47. Travis WD, Hoffman GS, Leavitt RY, Pass HI, Fauci AS: Surgical pathology of the lung in Wegener's granulomatosis. Review of 87 open lung biopsies from 67 patients. *Am J Surg Pathol* 15:315-33, 1991.
48. Hoffman GS, Filie JD, Schumacher HR Jr., Ortiz-Bravo E, Tsokos MG, Marini JC, Kerr GS, Ling A, Trentham DE: Intractable vasculitis, resorptive osteolysis, and immunity to type I collagen in Type VIII Ehlers-Danlos syndrome. *Arthritis Rheum* 34:1466-75, 1991.
49. Hoffman GS: Rheumatoid arthritis. In: Current Therapy in Allergy, Immunology, and Rheumatology - 4. Eds: L.M. Lichtenstein and A.S. Fauci, B.C. Decker Inc., pp. 158-63, 1992.

50. Hoffman GS: Dermatomyositis and polymyositis. In: Current Therapy in Allergy, Immunology, and Rheumatology - 4. Eds: L.M. Lichtenstein and A.S. Fauci, B.C. Decker Inc., pp. 199-201, 1992.
51. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS: Wegener's granulomatosis: a prospective analysis of 158 patients. *Ann Intern Med* 116:488-98, 1992.
52. Kerr GS, Hoffman GS: SLE and the cardiovascular system: vasculitis. In: Systemic Lupus Erythematosus, 2nd Edition. Ed: R.G. Lahita, Churchill Livingstone Inc., Chapter 31, pp. 719-29, 1992.
53. Hoffman GS, Leavitt RY, Kerr GS, Fauci AS: Treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. *Arthritis Rheum* 35:1322-9, 1992.
54. Lebovics RS, Hoffman GS, Leavitt RY, Kerr GS, Kammerer W, Hallahan CW, Fauci AS: The management of subglottic stenosis in Wegener's granulomatosis. *Laryngoscope*. 102:1341-5, 1992.
55. Hoffman GS, Fauci AS: Wegener's granulomatosis. In: Rheumatology, 1st Edition. Eds: J.H. Klippel and P. Dieppe, Mosby, London, June 9, 1993.
56. Cid MC, Fauci AS, Hoffman GS: The vasculitides: classification, diagnosis and pathogenesis. In: Connective Tissue Diseases: Selected Topics, 1st Edition. Eds: M.A. Khamashta, J. Font and G.R.V. Hughes, Doyma, S.A. 1993.
57. Hoffman GS, Fauci AS: Emerging concepts in the management of vasculitic diseases. Chapter 39. In: Advances in Internal Medicine. Ed: A.S. Fauci, 39:277-303, 1993.
58. Hoffman GS: Treatment of chronic idiopathic systemic vasculitides. In: Advances in Experimental Medicine and Biology. Ed: W. L. Gross, Plenum Press, 227-34, 1993.
59. Meier J, Hoffman GS: Mycobacterial and fungal infections: In: Textbook of Rheumatology, 4th Edition. Eds: W.N. Kelly, E.D. Harris Jr., S. Ruddy, C.B. Sledge, W.S. Saunders, 1993.
60. Kerr GS, Fleisher TA, Hallahan CW, Leavitt RY, Fauci AS, Hoffman GS: Limited prognostic value of changes in antineutrophil cytoplasmic antibody titers in patients with Wegener's granulomatosis. In: Advances in Experimental Medicine and Biology. Ed: W. L. Gross. Plenum Press, 1993.
61. Hoffman GS: Vasculitis: treatment. In: Primer on the Rheumatic Diseases, 10th Edition, 146-8, 1993.

62. Travis WD, Hoffman GS, Leavitt RY, Lebovics RS: Problems in interpretation of head and neck biopsies for the diagnosis of Wegener's granulomatosis. In: Intractable Vasculitis Syndromes. Ed: T. Tanabe, Hakkaido Univ. Press., Sapporo, Japan, pp. 27-52, 1993.
63. Rottem M, Fauci AS, Hallahan CW, Kerr GS, Lebovics R, Leavitt RY, Hoffman GS: A longterm prospective study of Wegener's granulomatosis in 23 children and adolescents: clinical presentation and outcome. *J Pediatr* 122:26-31, 1993.
64. Hoffman GS: Immunosuppressive therapy for autoimmune diseases. *Ann Allergy* 70:1-14, 1993.
65. Hoffman GS: Wegener's granulomatosis. *Curr Opin Rheumatol* 5:11-17, 1993.
66. Kerr GS, Fleisher TA, Hallahan CW, Leavitt RY, Fauci AS, Hoffman GS: Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. *Arthritis Rheum* 36:365-71, 1993.
67. Cid MC, Grant DS, Hoffman GS, Auerbach R, Fauci AS, Kleinman HK: Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. *J Clin Invest* 91:977-85, 1993.
68. Hoffman GS, Reginato A: Arthritis due to deposition of calcium crystals. Chapter 282. In: Harrison's Principles of Internal Medicine, 13th Edition. Eds: J.D. Wilson, et al., McGraw Hill, 1993.
69. Hoffman GS, Kerr GS: Diagnosis of systemic vasculitis in the acutely ill patient. In: Chapter 11. Management of the Critically Ill Patient With Rheumatic or Immunologic Disease, pp. 279-308, 1st Edition. Ed: B.F. Mandell, 1994.
70. Rottem M, Fauci AS, Hoffman GS: Familial vasculitis. a report of 2 families. *J Rheumatol* 21:561-3, 1994.
71. Mandell BF, Hoffman GS: Differentiating vasculitides. *Rheum Dis Clin North Am* 20(2):409-42, 1994.
72. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, Hoffman GS: Takayasu's arteritis. *Ann Intern Med* 120:919-29, 1994.
73. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg T, Gross WL, Hagen C, Hoffman GS, Hunder GG, Kallenberg CGM, McCluskey RT, Sinico RA, Rees AJ, Van Es LA, Waldherr R, Wiik A: Nomenclature of systemic vasculitides: the proposal of an International Consensus Conference. *Arthritis Rheum* 37:187-92, 1994.

74. Hoffman GS: Editor: Vasculitis Syndromes. Overview. *Current Opin Rheumatol* (Current Science) 6:1-2, 1994.
75. Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS: Treatment of glucocorticoid-resistant or relapsing Takayasu's arteritis with methotrexate. *Arthritis Rheum* 37:578-82, 1994.
76. Cid MC, Kleinman HK, Grant DS, Schnaper HW, Fauci AS, Hoffman GS: Estradiol enhances leukocyte binding to tumor necrosis factor (TNF)-stimulated endothelial cells via an increase in TNF-induced adhesion molecules E-selection, intercellular adhesion molecule type I and vascular cell adhesion molecule type I. *J Clin Invest* 93:17-25, 1994.
77. Hoffman GS: Hypertensive encephalopathy in a young man with undetectable upper extremity blood pressure. Vascular Medicine Grand Rounds. *J Vasc Med Biol* 5:69-73, 1994.
78. Hoffman GS: Wegener's granulomatosis 1931-1993: changing perceptions of a once fatal disease. *Cleve Clin J Med* 61:412-3, 1994.
79. Hoffman GS: Treating Wegener's granulomatosis: how far have we come? *Cleve Clin J Med* 61:414-5, 1994.
80. Galperin C, Hoffman GS: Antineutrophil cytoplasmic antibodies (ANCA). *Cleve Clin J Med* 61:416-27, 1994.
81. Hoffman GS, Fauci AS: Emerging concepts in the management of vasculitic diseases. *Advances Int Med* 39:277-301, 1994.
82. Giordano JM, Hoffman GS, Leavitt RY: Takayasu's disease. Chapter 12, pp. 245-53. In: Vascular Surgery. Ed: Rutherford, W.B. Saunders Co. Phila., 1995.
83. Ognibene FP, Shelhamer JH, Hoffman GS, Kerr GS, Reda D, Fauci AS, Leavitt RY: *Pneumocystitis carinii* pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. *Am J Respir Crit Care Med* 151:795-9, 1995
84. Fauci AS, Hoffman GS: Granulomatous hepatitis. Chapter 98. In: Principles and Practice of Infectious Diseases, 4th Edition, pp. 1159-64. Eds: G. Mandel, G.E. Bennett, R. Dolin. J. Wiley and Sons, Inc., 1995.
85. Cash JM, Hoffman G: Glucocorticoids. Chapter 126, pp.1947-58. In: Clinical Immunology. Editor: R. Rich, 1995.
86. Cash JM, Hoffman G: Immunomodulating pharmaceuticals. Chapter 129, pp. 1980-92. In: Clinical Immunology. Editor: R. Rich, 1995.

87. Hoffman GS: Advances in Wegener's granulomatosis. *Hospital Practice* 10:33-40, 1995.
88. Hoffman GS: Classics in Medicine: Wegener's granulomatosis: The path traveled since 1931. *Medicine* 73(6):325-9, 1995.
89. Duna GF, Hoffman GS: Immunosuppression: new perspectives in the treatment of the systemic vasculitides. *Ann Med Interne* 145:581-94, 1995.
90. Hoffman GS: Treatment of resistant Takayasu's arteritis. In: Clin Rheum Dis 21(1):73-80. Eds: J Cash, R. Wilder, 1995.
91. Wilke WS, Hoffman GS: Treatment of corticosteroid-resistant giant cell arteritis. In: Clin Rheum Dis 21(1):59-71. Eds: J. Cash, R. Wilder, 1995.
92. Calabrese LH, Hoffman GS, Guillivan L: Therapy of resistant systemic necrotizing vasculitis: polyarteritis, Churg Strauss, Wegener's granulomatosis and hypersensitivity vasculitis group disorders. In: Clin Rheum Dis 21(1):41-57. Eds: J. Cash, R. Wilder, 1995.
93. Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CE, Fauci AS: Wegener's granulomatosis: an analysis of 42 patients treated with methotrexate and prednisone. *Arthritis Rheum* 38:608-13, 1995.
94. Hoffman GS: Vasculitic syndromes. Editorial overview. *Curr Opin Rheumatol* 7:1-3, 1995.
95. Chen CC, Kerr GS, Carter CS, Read EJ, Carrasqillo JA, Leitman SF, Hoffman GS: Lack of sensitivity of indium-111 mixed leukocyte scans for active disease in Takayasu's arteritis. *J Rheumatol* 22:478-81, 1995.
96. Duna GF, Galperin C, Hoffman GS: Wegener's granulomatosis. *Rheum Dis Clinics NA* 21:949-86, 1995.
97. Cotch MF, Hoffman GS, Yerg DE, Kaufman GI, Targonski P, Kaslow RA: The epidemiology of Wegener's granulomatosis. *Arthritis Rheum* 39:87-92, 1996.
98. Hoffman GS: Takayasu's arteritis: lessons from the American National Institutes of Health experience. *Internat J Cardiol* 54(S):83-86, 1996.
99. Talar-Williams C, Hijazi YM, Walther MM, Linehan W, Hallahan CW, Lubensky I, Kerr G, Hoffman GS, Fauci AS, Sneller MC: Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener's granulomatosis. *Ann Intern Med* 124:477-84, 1996.
100. Langford CA, Sneller MC, Hallahan CW, Hoffman GS, Kammerer WA, Talar-Williams C, Fauci AS, Lebovics RS: Clinical features and management of subglottic stenosis in patients with Wegener's granulomatosis. *Arthritis Rheum* 39:1754-60, 1996.

101. Hoffman GS: Immunosuppressive therapy is always required for the treatment of limited Wegener's granulomatosis. Pro. Controversies in vasculitis. In: Sarcoidosis, Vasculitis and Diffuse Lung Disease, 13:249-52, 1996.
102. Cruz-Estaban C, Hoffman GS: The use of intravenous immunoglobulin in rheumatic diseases. *CCJM*, 63:340-343, 1996.
103. Cash JM, Hoffman GS: Rheumatoid arthritis. In: Current Therapy in Allergy, Immunology and Rheumatology. Ed: LM Lichtenstein and AS Fauci. Mosby, 5th Edition, 186-93, 1996.
104. Hoffman GS: ANCA's: Are they important? *J Nephrol* 9:1-3, 1996.
105. Reginato A, Hoffman GS: Arthritis due to deposition of calcium crystals. In: Harrison's Principles of Internal Medicine, 14th Edition. Eds: JD Wilson et al., McGraw Hill, 1997.
106. Hoffman GS: The perils of nontreatment of hyperuricemia. *CCJM* 64:215, 1997.
107. Hoffman GS: Vasculitis syndromes. *Curr Op Rheumatol* 9:1-2, 1997.
108. Calabrese LH, Hoffman, GS, Clough JD: Systemic vasculitis. Chapter 22. In: Peripheral Vascular Diseases. Edit: Young JR, Olin JW, Bartholomew JR. Mosby Year Book, St. Louis, 1997.
109. Hoffman GS: Vasculitis: treatment. In: Primer on the Rheumatic Diseases, 11th Edition. Ed: JH Klipper, Arthritis Foundation, 1997, pg 300-304.
110. Horvath J, Hoffman GS: Potential pitfalls in the treatment of systemic vasculitides. *Hosp Med* August 1997, pg 10-28.
111. George TM, Cash JM, Farver C, Sneller M, Van Dyke CW, Derus C, Hoffman GS: Mediastinal mass and hilar adenopathy: rare thoracic manifestations of Wegener's granulomatosis. *Arthritis Rheum* 40:1992-1997, 1997.
112. Hoffman GS: Editorial. Treatment of Wegener's granulomatosis: time to change the standard of care? *Arthritis Rheum* 40:2099-2104, 1997.
113. Edberg JC, Weinstein E, Wu J, Csernok E, Sneller MC, Hoffman GS, Keystone EC, Gross WL, Kimberly RP: Analysis of FcγR II gene polymorphisms in Wegener's granulomatosis. *Exp Clin Immunogenet* 14:183-95, 1997.
114. Langford CA, Sneller MC, Hoffman GS: Methotrexate use in systemic vasculitis. *Rheum Dis Clin NA* 23:841-853, 1997.

115. Sullivan EJ, Hoffman GS: Wegener's granulomatosis. *Sem Resp Crit Care Med* 19:13-25, 1998.
116. Hoffman GS: Vasculitis. Editorial overview. *Curr Opin Rheumatol* 10:1-2, 1998.
117. Hoffman GS: Classification of the systemic vasculitides: antineutrophil cytoplasmic antibodies, consensus and controversy. *Clin Exp Rheumatol* 16:111-115, 1998.
118. Horvath J, Hoffman GS: Systemic vasculitis. In: Textbook of Clinical Rheumatology. Ed: Hwee-Siew Howe and Pao Hsii Feng, National Arthritis Foundation, Singapore.1998. Pp.152-166.
119. Fessler BF, Hoffman GS: SLE and the cardiovascular system: vasculitis. In: Systemic Lupus Erythematosus, 3rd Edition. Ed: RG Lahita, Chapter 33.707-717, 1998.
120. Hoffman GS: Wegener's granulomatosis. Chapter 22. In: Rheumatology, 2nd Edition. Eds: JH Klippel and P. Dieppe, Mosby, London. Pp.22.1-10. 1998.
121. Hoffman GS, Specks U: Antineutrophil cytoplasmic antibodies. *Arthritis Rheum* 41:1521-37, 1998.
122. Hoffman GS, Specks U: Antineutrophil cytoplasmic antibodies. *Bull Rheum Dis.* 1998.
123. Hoffman, Drucker Y, Cotch MF, Locker GA, Easley K, Kwok K: Wegener's granulomatosis: Patient-reported effects of disease on health, function and income. *Arthritis Rheum* 41: 2257-62. 1998.
124. Hoffman GS: The differential diagnosis of polyarthritis. Chapter 29. In: Cleveland Clinic Intensive Review of Internal Medicine. Eds. Stoller JK, Longworth DL, Williams and Wilkins, Baltimore. pp. 289-302, 1998.
126. Hoffman GS: Vasculitis: Textbook of Rheumatology Update Series (monograph). WB Saunders, 28:1-18, 1998.
127. Lynch JP, Hoffman GS: Wegener's granulomatosis: controversies and current concepts. *Comprehensive Therapy*. 24:421-440, 1998.
128. Duna GF, Cotch MF, Galperin C, Hoffman DB, Hoffman GS: Wegener's granulomatosis: role of environmental exposures. *Clin Exp Rheumatol* 16:669-74, 1998.
129. Flamm SD, White RD, Hoffman GS: The clinical application of "edema-weighted" magnetic resonance imaging in Takayasu's arteritis. *Internat J Cardiol* 66 (S):151-159, 1998.

130. Hoffman GS, Ahmed AE for the International Network for the Study of the Systemic Vasculitides: Surrogate markers of disease activity in patients with Takayasu's arteritis. *Internat J Cardiol* 66 (S1):191-194, 1998.
131. Sullivan EJ, Hoffman GS: Pulmonary vasculitis. *Clin Chest Med* 19:759-776 1998.
132. Hoffman GS: Vasculitis syndromes. Editorial overview. *Curr Opin Rheumatol* 11:1-2, 1999.
133. Villa-Forte A, Hoffman GS: Wegener's granulomatosis presenting as a renal mass. *J Rheumatol* 26:457-8, 1999.
134. Horvath JR, Hoffman GS: Multicentric reticulohistiocytosis: a mimic of gout and rheumatoid arthritis. *Cleve Clin J Med* 66:166-170, 1999.
135. Santos-O'Campo A, Hoffman GS: Aneurysms and hypermobility. *Cleve Clin J Med* 66:426-33. 1999.
136. Mandell BF, Hoffman GS: Necrotizing systemic arteritis. In: Textbook of Dermatology in General Medicine. Eds: Fitzpatrick, et al, McGraw Hill, 1999. Chapter 175. 2034-2044.
137. Mandell BF and Hoffman GS: Systemic necrotizing arteritis. Current Practice of Medicine. Ed: R. Bone, Rapid Science Publishers 2:175-185, 1999.
138. Vassilopoulos D, Hoffman GS: Clinical utility of antineutrophil cytoplasmic antibody (ANCA) testing. *Clin Diag Lab Immunol* 6:645-51.1999.
139. Langford CA, Hoffman GS: Wegener's granulomatosis. *Thorax: Rare Diseases Series*. 54:629-37.1999.
140. Cid MC, Esparza J, Schnaper HW, Juan M, Yague J, Grant DS, Urbano-Marquez A, Hoffman GS, Kleinman HK. Estradiol enhances endothelial cell interactions with extracellular matrix proteins via an increase in integrin expression and function. *Angiogenesis*. 3:271-80.1999.
141. Langford CA, Hoffman GS: Methotrexate as an alternative to classical immunosuppressive therapies. In *Vasculitis*. Edit: Kallenberg C. 2001.
142. Giordano JM, Hoffman GS: Takayasu's disease: Non-specific aortoarteritis. Chapter 21, pp. 364-73. In: Vascular Surgery. Ed: Rutherford, W.B. Saunders Co. Phila., 2000.
143. Mandell BF, Hoffman GS: Rheumatic diseases and the cardiovascular system. Chapter 67. pp. 2199-2210. In: *Heart Disease: A Textbook of Cardiovascular Medicine*. 6th Edition. Edit: Braunwald E, Zipes DP, Libby P. WB Saunders Co., 2001.

144. Hoffman GS, Mandell BF: Vasculitis - Its many forms. Pp 1404-18. In Kelly's Textbook of Internal Medicine, 4th Edition. Edit: Humes HD, et.al. Lippincott, Williams and Wilkins, 2000.
145. Hoffman GS, Langford CA, Calabrese LH: Chapter 97. Vasculitis. Pp. 931-42. In Hospital Medicine. Edit: Wachter RM, Goldman L, Hollander H. Lippincott, Williams and Wilkins, Phila. 1st Edition . 2000.
146. Sridharan S, Mossad S, Hoffman G: Hepatitis A infection mimicking adult onset Still's disease. *J Rheumatol* 27:1792-5. 2000.
147. Mekhail TM, Hoffman GS: Longterm outcome of Wegener's granulomatosis in patients with renal disease requiring dialysis. *J Rheumatol* 27:1237-40. 2000.
148. Langford CA, Hoffman GS: Methotrexate as an alternative to classical immunosuppressive therapies. In: Vasculitis. Ed: Kallenberg C. 2000.
149. Rojo-Leyva F, Ratliff N, Cosgrove DM, Hoffman GS: Study of 52 patients with idiopathic aortitis from a cohort of 1,204 surgical cases. *Arthritis Rheum* 43:901-907. 2000.
150. Fernandes SRM, Singsen BH, Hoffman GS: Sarcoidosis and systemic vasculitis. *Sem Arthritis Rheum* 30:33-46. 2000.
151. Jolly M, Molta C, Hoffman G: Wegener's granulomatosis: Pitfalls in the management of pulmonary disease. *J Rheumatol* 27:2511-2. 2000.
152. Hoffman GS: Environmental factors in systemic vasculitis. *Clin Exp Immunol* 120 (suppl 1):10-11, 2000.
153. Hoffman GS: Collaborative studies in Europe and the USA: where to go? *Clin Exp Immunol* 120 (suppl 1):17, 2000.
154. Hoffman GS: Large vessel vasculitis. *Clin Exp Immunol* 120 (suppl 1):30-31, 2000.
155. Stone JJ, Hoffman GS: Vasculitis at the millennium. *Curr Opin Rheumatol* 12:1-2. 2000.
156. Stone JH, Hoffman GS, Merkel PA, Min Y-I, ML Uhlfelder ML et al.: A Disease-Specific Activity Index for Wegener's Granulomatosis: Modification of the Birmingham Vasculitis Activity Score. *Arthritis Rheum*. 44:912-920. 2001.
157. Lenardo TM, Hoffman GS: A 29 year old female with flank pain, hypertension and gross hematuria. In Internal Medicine Pearls II. Edit: Heffner JE and Sahn SA. 2000.

158. Stone JH, Calabrese LH, Hoffman GS, Pusey C, Hunder GG, Hellmann DB: Vasculitis: A collection of pearls and myths. In *Rheum Dis Clin.* 27: 677-728.2001.
159. Stone JH, Uhlfelder ML, Hellmann DB, Crook, Bedocs N-M, Hoffman GS. Etanercept combined with conventional treatment in Wegener's granulomatosis. *Arthritis Rheum.* 44:1149-54. 2001.
160. Hutson TE, Hoffman GS. Temporal concurrence of vasculitis and cancer: a report of 12 cases. *Arthritis Care Res.* 13:417-23. 2000.
161. Hoffman GS. The Vasculitides: Wegener granulomatosis and Churg Strauss vasculitis. In *Primer on the Rheumatic Diseases.* 2001.
162. Boomsma MM, Bijl M, Stegeman CA, Kallenberg CGM, Hoffman GS, Cohen Tervaert JW. Patients' perceptions of the effects of systemic lupus erythematosus on health, function, income, and interpersonal relationships; a comparison with Wegener's granulomatosis. In Press. *Arthritis Rheum/Arthritis Care Res.*
163. Hoffman GS, Gross W. Wegener's granulomatosis. Clinical features. In *Inflammatory Diseases of Blood Vessels.* Marcel Dekker, Inc. Editors: Hoffman GS, Weyand C: In press. 2001.
164. Rendt KE, Hoffman GS. Sarcoidosis and vasculitis . In *Inflammatory Diseases of Blood Vessels.* Marcel Dekker, Inc. Editors: Hoffman GS, Weyand C: In press. 2001.
165. Huang D, Zhou Y, Hoffman GS. Pathogenesis: Immunogenetic factors. In Alarcon G, Hoffman GS. *Clinical Rheumatology. Systemic Vasculitis.* 15:239-58.2001.
166. Stein J, Eliachar I, Sridharan S, Woods B, Hoffman GS. Nasal cavity squamous cell carcinoma in Wegener's granulomatosis. *Arch Otolaryngol Head Neck Surg.* 127:709-13.2001.
167. The WGET Research Group. Design of the Wegener's granulomatosis etanercept trial (WGET). *Controlled Clin Trials* (submitted, 2001).
168. Hoffman GS, Cid MC, Hellmann DB, Guillemin L et al. A multicenter randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. In press. 2001. *Arthritis Rheum.*
169. Stone JH, Hoffman GS. Wegener's Granulomatosis and Lymphomatoid Granulomatosis. In *RHEUMATOLOGY.* 3rd Edition. Harcourt Health Sciences. UK. Editors: Hochberg M et al. 2002.

Books:

1. Inflammatory Diseases of Blood Vessels. Marcel Dekker, Inc.
Editors: Hoffman GS and Weyand C. 2002.
2. Clinical Rheumatology. Systemic Vasculitis. Editors: Alarcon G and Hoffman GS.
Harcourt Publishers. 2001.

Electronic Publications**Up To Date 1997- present:**

1. Rose BD, King TE, Hoffman GS: Clinical manifestations of Wegener's granulomatosis.
 2. Hoffman GS: Treatment of Wegener's granulomatosis
 3. Rose BD, Appel GB, Kaplan AA, Hoffman GS: Treatment of Wegener's granulomatosis and microscopic polyangiitis.
 4. Rose BD, Appel GB, Hoffman GS: Alternative agents in the treatment of Wegener's granulomatosis and microscopic polyangiitis.
 5. Monev S, Hoffman GS: Pharmacology and side effects of cyclosporin and tacrolimus.
 6. Rose BD, Hoffman GS: Clinical spectrum of antineutrophil cytoplasmic antibodies.
 7. Rose BD, Hoffman GS: ANCA (antineutrophil cytoplasmic antibodies): pathogenesis.
 8. Wilke WS, Hoffman GS: Overview of the major antirheumatic drugs.
 9. Hoffman GS, Villa Forte A: General principals of the use of cyclophosphamide in rheumatic and renal diseases.
 10. Hoffman GS, Langford CA: Mechanism of action and general toxicity of alkylating agents.
-

Other electronic publications:

11. Shaw M, Hoffman GS: ACP-ASIM's PIER Project; Module: Vasculitis 2001.
12. Extensive writings RheumatologyWeb.com 1999- present.

ABSTRACTS

1. Hoffman GS, Kline I, Gang M, Tyrer DD, Goldin A, Venditti JM: Sequential chemotherapy with cyclophosphamide (NSC-26271) and cytosine arabinoside (NSC-63878) in mice with advanced leukemia L1210. *Proc Amer Assoc of Cancer Res* 9:31, 1968.

2. Hoffman GS, Myers RL, Stark F, Thoen CD: Septic arthritis associated with *Mycobacterium avium*: Case report and literature review. XIV International Congress of Rheumatology. Abstract #638, 1977.
3. Hoffman GS, Schumacher HR, Paul H, Cherian V, Reed R, Ramsay AG, Franck WA: Calcium oxalate microcrystalline arthritis in chronic renal failure. *Arthritis Rheum* 24:573, 1981.
4. Hoffman GS, Franck WA, Raddatz DA, Stallones L: Presentation, treatment and prognosis of idiopathic inflammatory muscle disease in a rural hospital. *Arthritis Rheum* 26:568, 1983.
5. Hoffman GS, Olsen JE: Pelvic and hip girdle tumors as a cause of hip pain. Northeast Regional ARA Meeting, 1986.
6. Sentochnik DE, Hoffman GS: Hypoparathyroidism due to progressive systemic sclerosis. N.E. Regional Meeting, ARA, 1986.
7. Giordano JM, Leavitt RY, Hoffman GS, Fauci AS: Experience with surgical treatment for Takayasu's disease. Eastern Vascular Society, 1988.
8. Hoffman GS, Sechler JMG, Gallin JI, Shelhamer JH, Suffredini A, Ognibene FP, Baltaro R, Fleisher TA, Leavitt RY, Tsokos M, Fauci AS: Bronchoalveolar lavage in Wegener's granulomatosis. *Arthritis Rheum* 32:S125, 1989.
9. Devaney K, Travis W, Hoffman GS, Leavitt RY, Lebovics R, Fauci AS: Interpretation of head and neck biopsies in Wegener's granulomatosis. *Modern Pathol* 2:24A, 1989.
10. Baltaro RJ, Hoffman GS, Fleisher TA: Anti-neutrophil cytoplasmic antibodies in Wegener's granulomatosis. *Am J Clin Pathol* 92:557, 1989.
11. Hoffman GS, Kerr GS: Gastrointestinal emergencies. Vasculitis and the gut. Holland Digestive Disease Week, 1989.
12. Baltaro RJ, Hoffman GS, Sechler JMG, Suffredini AF, Shelhamer JH, Fauci AS, Fleisher TA: IgG antineutrophil cytoplasmic antibodies are produced in the respiratory tract of patients with Wegener's granulomatosis. *Arthritis Rheum* 33:6S, 1990.
13. Hoffman GS, Leavitt RY, Fleisher TA, Minor JR, Fauci AS: Treatment of systemic vasculitides with intermittent high dose intravenous cyclophosphamide. *Arthriris Rheum* 33:14S, 1990.
14. Hoffman GS: Pulse cyclophosphamide therapy for Wegener's granulomatosis. International Society for Rheumatic Therapy, London, England, 1990.

15. Ehrenreich H, Hoffman GS, Anderson RW, Fox CH, Rieckmann P, Travis WD, Coligan JE, Kehrl JH, Fauci AS: Human macrophages express endothelins - novel cytokines with vasoactive properties. Second International Conference on Endothelin, Japan. *J Vasc Med Biol* 2:177, 1990.
16. Hoffman GS, Leavitt RY, Kerr GS, Hallahan CW, Lebovics RS, Fauci AS: Wegener's granulomatosis: Permanent disease morbidity in 158 patients. N.E. Regional American College of Rheumatology Meeting, National Meeting, *Arthritis Rheum* 34:S74, 1991.
17. Hoffman GS, Leavitt RY, Kerr GS, Hallahan CW, Lebovics RS, Fauci AS: Wegener's granulomatosis: Clinical profile and outcome in 158 patients. N.E. Regional American College of Rheumatology Meeting, National Meeting, *Arthritis Rheum* 34:S74, 1991.
18. Cid M, Kleinman H, Grant D, Fauci AS, Hoffman GS: Estradiol increases leukocyte adhesion to TNF-stimulated endothelial cell monolayers: Implications for the pathogenesis of Takayasu's arteritis. American Federation of Clinical Research, American College of Rheumatology, *Arthritis Rheum* 34:S169, 1991.
19. Travis WD, Hoffman GS, Leavitt RY, Pass HI, Fauci AS: Surgical pathology of the lung in Wegener's granulomatosis. International Conference Supplement, *Am Rev Resp Dis* 143:A220, 1991.
20. Cid MC, Grant DS, Hoffman GS, Fauci AS, Kleinman HK: Haptoglobin-stimulation of angiogenesis in the systemic vasculitides. American College of Rheumatology, National Meeting, *Arthritis Rheum* 34:S117, 1991.
21. Hoffman GS, Leavitt RY, Kerr GS, Fauci AS: Treatment of Takayasu's arteritis with methotrexate. American College of Rheumatology, National Meeting, *Arthritis Rheum* 34:S74, 1991.
22. Lebovics RS, Hoffman GS, Leavitt RY, Kerr GS, Kammerer W, Hallahan CW, Fauci AS: The management of subglottic stenosis in Wegener's granulomatosis. Eastern Section of The Triological Society, 1992.
23. Kerr GS, Fauci AS, Leavitt RY, Fleisher TA, Hallahan CW, Hoffman GS: Limited prognostic value of the antineutrophil cytoplasmic antibody (C-ANCA) in patients with Wegener's granulomatosis. The 4th International Workshop on ANCA. The 2nd International Colloquium on Wegener's granulomatosis and vasculitic disorders. Lubeck, Germany 1992. The American College of Rheumatology S.E. Regional and National Meetings, *Arthritis Rheum* 1992;35(S)R5.
24. Hoffman GS: Treatment of the vasculitides. State of the Art. The 2nd International Colloquium on Wegener's Granulomatosis and Vasculitic Disorders. Lubeck, Germany, 1992.

25. Hoffman GS, Leavitt RY, Kerr GS, Fauci AS: The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. American College of Rheumatology, National Meeting, *Arthritis Rheum* 36, 1992.
26. Rottem M, Fauci AS, Hallahan CW, Kerr GS, Lebovics R, Leavitt RY, Hoffman GS: A longterm prospective study of Wegener's granulomatosis in 23 children and adolescents: clinical presentation and outcome. American College of Rheumatology, National Meeting, 1992.
27. Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS: Treatment of Takayasu's arteritis with methotrexate. American College of Rheumatology. Colorado, 1993.
28. Kerr GS, Hallahan CW, Leavitt RY, Fauci AS, Hoffman GS: A study of 60 patients with Takayasu's arteritis: Presentation, treatment and long-term outcome. American College of Rheumatology. Colorado, 1993.
29. Hoffman GS: Granulomatous vasculitides and the evolving story of antineutrophil cytoplasmic antibodies. American College of Rheumatology, 1993.
30. Cotch MF, Hoffman GS: The epidemiology of Wegener's granulomatosis: how rare is it? American College of Rheumatology 58th Annual Scientific Meeting, 1994, Arthritis Rheum 37:S408.
31. Sneller MC, Talar-Williams C, Hallahan C, Kerr GS, Hoffman GS, Fauci AS: Analysis of 42 patients with Wegener's granulomatosis treatment with low dose methotrexate plus glucocorticoids. American College of Rheumatology 58th Annual Scientific Meeting, 1994, *Arthritis Rheum* 37:S353.
32. Cid MC, Esparza J, Morales D, McGowan KA, Grant DG, Urbano-Marquez A, Schnaper HW, Hoffman GS, Kleinman HK: Estradiol enhances endothelial cell attachment to extracellular matrix proteins through an increase in integrin expression. American College of Rheumatology 59th Annual Scientific Meeting, 1995, *Arthritis Rheum* 38:S16.
33. Cotch MF, Hoffman GS: The prevalence, epidemiology and cost of hospitalizations for vasculitis in New York State: 1986 to 1990. American College of Rheumatology 59th Annual Scientific Meeting, 1995, *Arthritis Rheum* 38:S434.
34. Wainstein E, Edberg JC, Dow D, Csernok E, Sneller M, Keystone E, Gross W, Hoffman G, Kimberly RP: FcγRIIIB alleles are significantly skewed in Wegener's granulomatosis (WG). American College of Rheumatology 59th Annual Scientific Meeting, 1995, *Arthritis Rheum* 38:S1333.

35. Langford CA, Sneller MC, Hallahan CW, Hoffman GS, Kammerer WA, Talar-Williams C, Fauci AS, Lebovics RS: Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis. American College of Rheumatology 59th Annual Scientific Meeting, 1995, *Arthritis Rheum* 38:S1424.
36. Talar-Williams C, Hijazi Y, Walther M, Hallahan CW, Kerr GS, Hoffman GS, Lubensky I, Fauci AS, Sneller MC: Cyclophosphamide-induced bladder toxicity in patients with Wegener's granulomatosis. American College of Rheumatology 59th Annual Scientific Meeting, 1995, *Arthritis Rheum* 38:S1425.
37. Flamm SD, VanDyke C, White RD, Hoffman GS: Novel magnetic resonance imaging (MRI) techniques for evaluating active arterial inflammation in Takayasu's disease (TD). American College of Rheumatology 60th Annual Scientific Meeting, *Arthritis Rheum* 39(S):201, 1996.
38. Duna GD, Cotch MF, Galperin C, Hoffman D, Hoffman GS: Wegener's granulomatosis (WG): Role of environmental exposures. American College of Rheumatology 60th Annual Scientific Meeting, *Arthritis Rheum* 39:(S):198, 1996.
39. Cash JM, George TM, Farver C, Sneller M, Derus CL, Hoffman GS: Mediastinal mass and hilar adenopathy in Wegener's granulomatosis. International ANCA Workshop, Mayo Clinic, 1996.
40. Wainstein E, Edberg J, Csernok E, Sneller M, Hoffman G, Keystone E, Gross W, Salmon J, Kimberly R: Fc γ R III B alleles predict renal dysfunction in Wegener's granulomatosis (WG). American College of Rheumatology 60th National Scientific Meeting, *Arthritis Rheum* 39(S):210, 1996.
41. Hoffman GS: Multicenter studies to identify improved serologic markers of active vasculitis. International Conference on Takayasu Arteritis, 1996.
42. Flamm SD, Van Dyke C, White RD, Hoffman GS: Improved MRA imaging techniques for large vessel inflammatory diseases. International Conference on Takayasu Arteritis, 1996.
43. Wu J, Edberg J, Csernok E, Sneller M, Hoffman G, Keystone E, Gross W, Kimberly R: Fc γ RIIIA alleles associate Wegener's granulomatosis (WG). Biomedicine Conference, 1997.
44. Hoffman GS: Management of Takayasu's arteritis. ILAR Conference, 1997.
45. Hoffman GS: Pathogenesis of ANCA-associated vasculitides. ILAR Conference, 1997.

46. Hoffman GS: Dilemmas in vasculitis: diagnosis and treatment. ILAR Conference, 1997.
47. Hoffman GS: Recent advances in vasculitis. ILAR Conference, 1997.
48. Hoffman GS: Systemic vasculitis. classification criteria, consensus and controversy. American College of Rheumatology, November 1997.
49. Mekhail TM, Hoffman GS: Long-term outcome of Wegener's in patients with renal disease requiring dialysis. *Arthritis Rheum* 40:S166, 1997 and 8th International ANCA-Vasculitis Workshop. *Clin Exp Immunology* 12:58.1998.
50. Kimberly RP, Edberg JC, Wainstein E, Csernok E, Sneller M, Hoffman G, Keystone E, Gross WL: Association of the FcgRIIb-NA1 allele with renal disease in Wegener's granulomatosis. 8th International ANCA-Vasculitis Workshop. *Clin Exp Immunology* 112:28.1998.
51. Hoffman GS, Drucker Y, Easley K, Kwok K, Cotch MF. Wegener's granulomatosis: Patient - reported effects of disease on health, function and income. 8th International ANCA-Vasculitis Workshop. *Clin Exp Immunology* 112:29.1998.
52. Hoffman GS: Vasculitis: treatment-related morbidity and mortality. 8th International ANCA-Vasculitis Workshop. *Clin Exp Immunology* 112:8.1998.
53. Vasculitis activity score for Wegener's granulomatosis. A report from the International Network For the Study of Systemic Vasculitides (INSSYS). *Arthritis Rheum* 42:S:1999.
54. Stone JH, Hellmann DB, Uhfelder ML, Bedocs NM, Crook SL, Holbrook J, Hoffman GS: Etanercept in Wegener's granulomatosis. Results of an open label trial. *Arthritis Rheum* 42:S:1999.
55. Hutson TE, Hoffman GS: Temporal occurrence of vasculitis and cancer: a report of 12 cases. *Arthritis Rheum* 42:S:1999.
56. Vassilopoulos D, Niles JL, Villa-Forte A, Arroliga AC, Sullivan, Merkel PA, Hoffman GS : Prevalence of antineutrophil cytoplasmic antibodies (ANCA) in patients with various pulmonary diseases or multiorgan dysfunction. *Arthritis Rheum* 42:S:1999.
57. Hoffman GS, Tso E, White RD, Flamm SD: Takayasu's arteritis: utility of magnetic resonance imaging in diagnosis and treatment. *Arthritis Rheum* 42:S:1999.
59. Vassilopoulos D, Niles JL, Villa-Forte A, Arroliga AC, Sullivan, Merkel PA, Hoffman GS : Prevalence of antineutrophil cytoplasmic antibodies (ANCA) in patients with

- various pulmonary diseases or multiorgan dysfunction. *Clin Exp Immunol* 120 (suppl 1):86, 2000.
60. Hoffman GS, Tso E, White RD, Flamm SD: Takayasu's arteritis: utility of magnetic resonance imaging in diagnosis and treatment. *Clin Exp Immunol* 120 (suppl 1):118, 2000.
 61. Hoffman GS, Cid M, Hellmann D, Merkel P, et al. for the International Network for the Study of Systemic Vasculitides (INSSYS). A multicenter placebo-controlled study of methotrexate (MTX) in giant cell arteritis (GCA). *Arthritis Rheum*. 2000.
 62. Luqmani R, Hoffman GS, Stone J: Modified Birmingham Vasculitis Activity Score for Wegener's granulomatosis (BVAS/WG) - feasibility and construct validity. *Arthritis Rheum*. 2000.
 63. Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS: Etanercept in Wegener's Granulomatosis: A Six-Month Open-Label Trial to Evaluate Safety. *Arthritis Rheum*. 2000.
 64. Fernandes SRM, Singsen BH, Hoffman GS: Sarcoidosis and systemic vasculitis. *Arthritis Rheum*. 2000.
 65. Gordon L, Goodlick L, Hoffman G: Giant cell arteritis (GCA) - characterization of candidate microbial sequences and evidence of immunologic relevance. *Arthritis Rheum*. 2000.
 66. Hoffman GS, Thomas CK, Eliachar I. Effective therapy for subglottic stenosis in Wegener's granulomatosis. *Arthritis Rheum* 44(S):17.2001.
 67. Hoffman GS, Thomas, CK, Wilke WS, Fessler B, Mandell BF. Open label trial of tamoxifen in scleroderma. *Arthritis Rheum* 44(S):1663.2001.
 68. Maiden N, Luqmani R, Uhlfelder ML, Merkel PA, Hoffman GS, Stone JH. Modified Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG)-feasibility and construct validity.2001.
 69. Zhou Y, Huang D, Hoffman GS. Genetic polymorphisms in TNF, IL-1, IL-6 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) in Wegener's granulomatosis. *Arthritis Rheum* 44(S):344.2001.
 70. Zhou Y, Huang D, Farver C, Hoffman GS. Influence of CCR5, CCR5 Δ 32, RANTES and MIP chemokines in Wegener's granulomatosis. *Arthritis Rheum* 44(S):391.2001.

71. Hellmann DB, Uhlfelder ML, Stone JH, Jenckes MW, Cinta-Cid M, Guillevin L, Moreland L, Dellarippa P, Hoffman GS, Merkel PA, Spiera R, Brown L, Rubin H. A giant cell arteritis-specific quality of life instrument. *Arthritis Rheum* 44(S):57.2001.

APPEARS THIS WAY
ON ORIGINAL